MARKET

MIRA

MIRA

Mira Pharma
NASDAQ
0.9751
+0.0041
+0.42%
After Hours: 0.9700 -0.0051 -0.52% 18:34 05/14 EDT
OPEN
0.9500
PREV CLOSE
0.9710
HIGH
0.9990
LOW
0.9500
VOLUME
130.69K
TURNOVER
--
52 WEEK HIGH
2.450
52 WEEK LOW
0.9000
MARKET CAP
40.98M
P/E (TTM)
-0.7220
1D
5D
1M
3M
1Y
5Y
1D
Mira Pharmaceuticals Q1 net loss narrows to $1.15 million; revenue flat at no revenue
PUBT · 8h ago
Psychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings
TipRanks · 9h ago
Mira announces results from Phase 1 trial evaluating Ketamir-2
TipRanks · 11h ago
MIRA Pharma Announces Unblinded Results From Completed Phase 1 Clinical Trial Evaluating Ketamir-2, Proprietary Selective Oral NMDA Receptor Modulator
Benzinga · 15h ago
MIRA Pharmaceuticals Reports Positive Phase 1 Ketamir-2 Results
TipRanks · 1d ago
Mira Pharmaceuticals publishes investor presentation on Ketamir-2 for chemotherapy-induced peripheral neuropathy
PUBT · 1d ago
Mira Pharma reports positive Phase 1 results for Ketamir-2 oral NMDA modulator
PUBT · 1d ago
Mira announces acceptance of peer-reviewed SKNY-1 manuscript
TipRanks · 1d ago
More
About MIRA
MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.

Webull offers Mira Pharmaceuticals Inc stock information, including NASDAQ: MIRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MIRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MIRA stock methods without spending real money on the virtual paper trading platform.